Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Paring Down Essential Medicines List In Sweeping Health System Reforms

This article was originally published in PharmAsia News

Executive Summary

[Editor's note: This is part three in a new series on China's wide-ranging plans to reform the country's health system, including its hospitals, insurance schemes, and access to medicines. Part one in the series appeared in PharmAsia News Oct. 30, 2008, and part two appeared Nov. 13, 2008.]

You may also be interested in...



China Needs To Balance Equal Access To Affordable Medicines With Sharpening Focus On Innovative Drugs In Mapping Out Future, Say Leaders At DIA Conference

BEIJING - As China launches sweeping health system reforms in phases over the next decade, the country must balance competing interests in mapping out the future: laying the groundwork for affordable and ultimately universal coverage while promoting the development of research- and capital-intensive innovative medicines, according to drug industry, academic and policy-making leaders who provided glimpses of the road ahead during the second annual meeting of the Drug Information Association in China

China Needs To Balance Equal Access To Affordable Medicines With Sharpening Focus On Innovative Drugs In Mapping Out Future, Say Leaders At DIA Conference

BEIJING - As China launches sweeping health system reforms in phases over the next decade, the country must balance competing interests in mapping out the future: laying the groundwork for affordable and ultimately universal coverage while promoting the development of research- and capital-intensive innovative medicines, according to drug industry, academic and policy-making leaders who provided glimpses of the road ahead during the second annual meeting of the Drug Information Association in China

Powerful Chinese Government Commission Set To Issue Price Caps For Essential Drug List Medicines

BEIJING - China's powerful National Development and Reform Commission, which has a virtually unrestricted purview over setting prices for medicines that are included on the country's Essential Drug List, is in the final stages of determining caps for every item on the newly revised list

Related Content

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel